新型俄罗斯放射性药物 Lu-DOTA-PSMA 的治疗功效的临床前研究。
Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical Lu-DOTA-PSMA.
机构信息
A. F. Tsyb Medical Radiological Research Center - Affiliated Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia.
National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia.
出版信息
Bull Exp Biol Med. 2023 Dec;176(2):224-226. doi: 10.1007/s10517-024-05999-z. Epub 2024 Jan 9.
The therapeutic efficacy of a Russian radiopharmaceutical Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of Lu-DOTA-PSMA.
采用前列腺癌 22Rv1 异种移植瘤抑制肿瘤生长的标准，研究了俄罗斯放射性药物 Lu-DOTA-PSMA 的治疗效果。用 Lu-DOTA-PSMA 治疗的小鼠的平均肿瘤体积明显低于对照组动物。接受 3.7 或 7.4MBq Lu-DOTA-PSMA 的动物组之间的肿瘤生长抑制值没有显著差异。
Zotero 插件